Jessen P, Nielsen B, Jensen I M, Ellegaard J, Hokland P
Arhus Amtssygehus, Medicinsk-haematologisk afdeling.
Ugeskr Laeger. 1992 Dec 21;154(52):3754-7.
We have evaluated the effect of intravenous infusions of granulocyte-macrophage colony-stimulating factor (GM-CSF) in ten patients undergoing autologous bone marrow transplantation after total body irradiation (11 Gy) and cyclophosphamide (120 mg/kg) conditioning for malignant lymphomas or acute lymphoblastic leukaemias. Mild side effects related to GM-CSF were seen in six patients, of whom one chose to discontinue treatment. Compared to a historic control group consisting of six patients treated with an identical conditioning regimen, a tendency was seen towards a more rapid neutrophil regeneration and a decreased need for erythrocyte transfusions. Moreover, a statistically significant improvement in thrombocyte related parameters was demonstrated. In contrast, there were no significant differences in severe toxicity, days on i.v. antibiotics, septic episodes or duration of hospitalization. In conclusion, it seems that GM-CSF treatment is of value in patients undergoing AKMT.
我们评估了粒细胞巨噬细胞集落刺激因子（GM-CSF）静脉输注对10例接受全身照射（11 Gy）和环磷酰胺（120 mg/kg）预处理以治疗恶性淋巴瘤或急性淋巴细胞白血病后进行自体骨髓移植患者的影响。6例患者出现了与GM-CSF相关的轻微副作用，其中1例选择停止治疗。与由6例接受相同预处理方案治疗的患者组成的历史对照组相比，观察到中性粒细胞再生更快且红细胞输血需求减少的趋势。此外，血小板相关参数有统计学上的显著改善。相比之下，在严重毒性、静脉使用抗生素的天数、败血症发作或住院时间方面没有显著差异。总之，GM-CSF治疗似乎对接受自体骨髓移植的患者有价值。
